About Benitec Biopharma Ltd
Benitec Biopharma was founded in 1997 and has been publicly listed on the ASX since then. During the mid 2000's, Benitec was involved in a lengthy and ultimately successful patent litigation, which included defense of our platform technology patents. This action resulted in their being re-examined and re-issued in all jurisdictions by 2012.
Benitec Biopharma is developing therapeutic agents in-house for use with human conditions of high prevalence and value. In addition, we out-license our proprietary technology to biotechnology and biopharma companies for use in non-core therapeutic areas, such as HIV/AIDS, Retinitis Pigmentosa, Huntington's Disease, and human cancer vaccines. We also licence the technology as a research agent and cross-license in other situations.
Business Development Associate Director, University of Michigan
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Business Development at Accelera Srl, Accelera - A company of NMS Group
Senior Finance Business Partner at Astrazeneca, AstraZeneca
Research on Host cell Interaction - Mass Spectrometry at Ernst Moritz Arndt - Universitat Greifswald, Ernst Moritz Arndt - Universitat Greifswald
Regulatory Affairs Specialist في Vitabiotics-Egypt, Vitabiotics-Egypt
CEO & Co-Founder, Zapnito
Managing Director, Thoroughly Good Consulting
Global Manager, Business Development, Nature Publishing Group
Former Head of Communities, Springer Nature